Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal

NEW YORK (TheStreet) -- Shares of Repros Therapeutics  (RPRX) skyrocketed 47.6% to $9.52 in morning trading Friday after the biopharmaceutical company held what it called a "constructive meeting" with the FDA regarding its expected New Drug Application (NDA) submission for its testosterone-boosting drug Androxal.

The company said the FDA does not think any further clinical studies would be required for filing the NDA. The FDA did note its interest in the drug's cardiovascular risk and mentioned additional safety studies could be required in this regard, though it did not make a specific request.

Repros said it does not think an additional meeting will be held before it submits the NDA.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

RPRX Chart RPRX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Facebook's Investors Have a Big Day Ahead

Facebook's Investors Have a Big Day Ahead

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

The Global Stock Market Rout Spreads Across the World

The Global Stock Market Rout Spreads Across the World

Comcast Details $30 Billion Bid for Britain's Sky in Takeover Battle With Fox

Comcast Details $30 Billion Bid for Britain's Sky in Takeover Battle With Fox

Credit Suisse Shares Surge After Strong Q1, Record Wealth Management Inflows

Credit Suisse Shares Surge After Strong Q1, Record Wealth Management Inflows